^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Hyaluronidase stimulant

    Related drugs:
    2d
    Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy. (PubMed, Clin Cancer Res)
    Sequential VCN-01 plus durvalumab was better tolerated than concomitant treatment. The recommended VCN-01 phase 2 dose (RP2D) was 1.0E13 vp, on the sequential schedule. Encouraging survival was observed in patients after progressing on anti-PD-(L)1 agents. Data supports VCN-01 replication associated with increased PD-1, PD-L1, and CD8 tumor expression. Sequential systemic delivery of VCN-01 and anti-PD-L1 therapy may represent an improved treatment for HNSCC.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)
    7ms
    Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=110, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • pegvorhyaluronidase alfa (PEGPH20)
    7ms
    TAK-771-3002: A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) (clinicaltrials.gov)
    P3, N=26, Active, not recruiting, Takeda | Trial completion date: Oct 2025 --> May 2026
    Trial completion date
    7ms
    A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants (clinicaltrials.gov)
    P3, N=15, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    10ms
    A Study of TAK-881 and HyQvia in Healthy Adults (clinicaltrials.gov)
    P1, N=30, Completed, Takeda | Recruiting --> Completed
    Trial completion
    11ms
    Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor-Stroma Ratio and Promote Cancer Progression. (PubMed, Cancer Res)
    Importantly, mTOR inhibitors synergistically enhanced the antitumor effects of stroma-targeting PEGPH20 in vivo in pNETs. Overall, this study revealed that cancer cell-derived ApoE could induce TipECs to remodel the TSR and that mTOR inhibitors could increase the efficacy of stroma-targeting therapies. Secretion of ApoE by pancreatic neuroendocrine tumor cells engenders a stroma-rich microenvironment, which can be reversed with mTOR inhibitors as part of combination strategies targeting the tumor stroma.
    Journal
    |
    APOE (Apolipoprotein E) • ATF6 (Activating Transcription Factor 6)
    |
    pegvorhyaluronidase alfa (PEGPH20)
    12ms
    A Phase I Study to Evaluate the Safety and Drug Allergy of HLB3-002 in Healthy Volunteers (clinicaltrials.gov)
    P1, N=243, Completed, Huonslab Co., Ltd. | Recruiting --> Completed
    Trial completion
    12ms
    TAK-771-3002: A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) (clinicaltrials.gov)
    P3, N=26, Active, not recruiting, Takeda | Trial completion date: Jun 2025 --> Oct 2025
    Trial completion date
    1year
    TAK-881-3003: A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (clinicaltrials.gov)
    P3, N=59, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    1year
    HYbISCUE: A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    1year
    A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants (clinicaltrials.gov)
    P3, N=15, Active, not recruiting, Takeda | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
    Trial completion date • Trial primary completion date
    1year
    A Study of TAK-881 and HyQvia in Healthy Adults (clinicaltrials.gov)
    P1, N=30, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open